Skip to content
10-K

Annual Report

ROIVANT SCIENCES LTD. ROIV

0001635088-26-000061

← back to feed
Filed
May 20, 2026 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding FY 2025 · May 12, 2026 719.27M sh
Shares Diluted FY 2025 · Mar 31, 2026 693.86M sh
Shares Diluted FY 2025 · Mar 31, 2025 725.4M sh
Shares Diluted FY 2025 · Mar 31, 2024 831.05M sh
Capex FY 2025 · Mar 31, 2026 $8.21M
Capex FY 2025 · Mar 31, 2025 $4.6M
Capex FY 2025 · Mar 31, 2024 $1.38M
Operating Cash Flow FY 2025 · Mar 31, 2026 −$750.35M
Operating Cash Flow FY 2025 · Mar 31, 2025 −$839.45M
Operating Cash Flow FY 2025 · Mar 31, 2024 −$765.27M
Cash And Equivalents FY 2025 · Mar 31, 2026 $1.42B
Cash And Equivalents FY 2025 · Mar 31, 2025 $2.72B
Stockholders Equity FY 2025 · Mar 31, 2026 $4.53B
Stockholders Equity FY 2025 · Mar 31, 2025 $4.69B
Current Liabilities FY 2025 · Mar 31, 2026 $281.24M
Current Liabilities FY 2025 · Mar 31, 2025 $149.41M
Total Liabilities FY 2025 · Mar 31, 2026 $416.28M
Total Liabilities FY 2025 · Mar 31, 2025 $249.74M
Current Assets FY 2025 · Mar 31, 2026 $5.17B
Current Assets FY 2025 · Mar 31, 2025 $5B
Total Assets FY 2025 · Mar 31, 2026 $5.71B
Total Assets FY 2025 · Mar 31, 2025 $5.44B
Eps Diluted FY 2025 · Mar 31, 2026 −$0.54
Eps Diluted FY 2025 · Mar 31, 2025 −$0.24
Eps Diluted FY 2025 · Mar 31, 2024 $5.23
Eps Basic FY 2025 · Mar 31, 2026 −$0.43
Eps Basic FY 2025 · Mar 31, 2025 −$0.24
Eps Basic FY 2025 · Mar 31, 2024 $5.55
Rd Expense FY 2025 · Mar 31, 2026 $681.81M
Rd Expense FY 2025 · Mar 31, 2025 $550.41M
Rd Expense restated FY 2025 · Mar 31, 2024 $439.91M
Net Income FY 2025 · Mar 31, 2026 −$299.77M
Net Income FY 2025 · Mar 31, 2025 −$171.98M
Net Income FY 2025 · Mar 31, 2024 $4.35B
Operating Income FY 2025 · Mar 31, 2026 −$515.07M
Operating Income FY 2025 · Mar 31, 2025 −$1B
Operating Income restated FY 2025 · Mar 31, 2024 $4.5B
Revenue FY 2025 · Mar 31, 2026 $8.26M
Revenue FY 2025 · Mar 31, 2025 $29.05M
Revenue restated FY 2025 · Mar 31, 2024 $32.71M